Financials

  • Market Capitalization 16.4 M
  • Employee 21
  • Founded 1980
  • CEO N/A
  • Website www.lisata.com
  • Headquarter Delaware, United States
  • FIGI BBG000BNVDR4
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.97
Price to sales ratio
95.05

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
4642
PLUR
Pluri Inc. - Common Stock
1.53 USD+3.38%-10.00%-8.38%-59.97%16.51 M USD
4644
NCEL
NewcelX Ltd. - Ordinary Shares
3.42 USD+1.18%+5.88%-3.39%-32.68%16.41 M USD
4649
CALC
CalciMedica, Inc. - Common Stock
0.47 USD-20.34%-20.34%-32.86%-82.78%16.05 M USD
4651
TPST
Tempest Therapeutics, Inc. - Common Stock
1.08 USD0.00%+6.93%+27.06%-54.81%15.99 M USD

Frequently asked questions about Lisata Therapeutics, Inc. Common Stock

What is the Lisata Therapeutics, Inc. Common Stock stock price today?

The current price of Lisata Therapeutics, Inc. Common Stock (LSTA) is 1.82. Over the past 24 hours, the stock has changed by +0.55%. Follow the LSTA chart for real-time price dynamics.

What is the stock ticker of Lisata Therapeutics, Inc. Common Stock?

Lisata Therapeutics, Inc. Common Stock trades under the ticker LSTA. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Lisata Therapeutics, Inc. Common Stock stock going up?

LSTA has changed by +63.96% over the last week, +59.65% over the last month, and -21.21% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Lisata Therapeutics, Inc. Common Stock?

Lisata Therapeutics, Inc. Common Stock currently has a market capitalization of 16.4 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Lisata Therapeutics, Inc. Common Stock earnings last quarter?

Last quarter, Lisata Therapeutics, Inc. Common Stock reported earnings of -0.32 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Lisata Therapeutics, Inc. Common Stock revenue for the last quarter?

Lisata Therapeutics, Inc. Common Stock reported quarterly revenue of 0. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Lisata Therapeutics, Inc. Common Stock net income for the last quarter?

Lisata Therapeutics, Inc. Common Stock reported net income of -2.93 M for the last quarter. The previous quarter showed -4.49 M, which means net income changed by +34.75%.

How many employees does Lisata Therapeutics, Inc. Common Stock have?

As of the latest available data, Lisata Therapeutics, Inc. Common Stock has 21 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Lisata Therapeutics, Inc. Common Stock stock?

You can buy Lisata Therapeutics, Inc. Common Stock (LSTA) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Lisata Therapeutics, Inc. Common Stock stock?

Investing in Lisata Therapeutics, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the LSTA chart and related analysis on metatrader.com as part of your research.

Lisata Therapeutics, Inc. - Common Stock

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

News